Last updated 2026-06-18
- Raised $10M funding round led by NFX Capital, Mar 2025
- Raised $10M funding round led by NFX Capital, May 2024
- Raised $5M funding round led by Fresh Fund, Dec 2022
Total raised
$25.0M
Last: 2025-07
Stage
Seed
Founded
2021
Headcount
59
HQ
Ramat Gan, Israel
Sector
Health Tech & Life Sciences
About
Remepy is pioneering hybrid drugs, and redefining combination therapy. Its mission is to bring better personalized care to patients.
Remepy’s Digital molecules are mobile applications designed for hybrid drug experiences, each containing a unique digital treatment protocol. Its Digital molecules include digitized, standardized, evidence-based interventions, designed to enhance brain plasticity and connectivity, balance the immune system, and drive behavioral changes. The company addresses disease end-points as well as side-effects and disease comorbidities.
Remepy partners with pharma companies to bring Hybrid Drugs to market that will combine Remepy’s Digital Molecule and traditional drug components.
Funding history · 4 rounds · $25.0M total
2025-07
Undisclosed
2025-03
$10.0M
2024-05
Q&A
- What is Remepy's core business?
- Remepy is pioneering hybrid drugs by combining traditional drug components with its 'Digital Molecules,' which are mobile applications containing unique digital treatment protocols. These digital molecules are designed to enhance brain plasticity, balance the immune system, and drive behavioral changes for personalized patient care.
- When was Remepy founded?
- Remepy was founded in December 2021.
- What is Remepy's employee count?
- Remepy has an employee count in the 51-200 range.
- Who are the co-founders of Remepy?
- The co-founders of Remepy are Or Shoval (Co-founder & CEO), Michal Tsur (Co-founder & CEO), and Shahar Shelly (Co-founder & CMO).
- What was Remepy's most recent funding round?
- In July 2025, Remepy received funding from Israeli Mapped in NY Ventures.
- Which investors participated in Remepy's March 2025 funding round?
- In March 2025, Remepy received funding from NFX Capital.
- What were the results of Remepy's Phase IIa clinical trial for Hybridopa?
- In May 2026, Remepy reported strong Phase IIa clinical trial results for Hybridopa, a hybrid drug for Parkinson's disease.
- What new evidence did Remepy publish in July 2026 regarding Hybridopa?
- In July 2026, Remepy published new mechanistic findings in npj Parkinson's Disease, showing Hybridopa's effect on structural connectivity in the brain of Parkinson's patients, which was associated with improved clinical outcomes.
- What was the focus of Remepy's mobile app in June 2025?
- In June 2025, Remepy's mobile app was shown to rewire the brain, modulate the immune system, and improve mood in adults with subjective cognitive decline.
- What is Remepy's plan regarding AI in its digital therapeutics?
- In June 2025, Remepy announced its intention to embed AI in next-generation digital therapeutics for personalized neuroimmune modulation.
Team · 3
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesDigital HealthcareMedical Decision SupportPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Platforms & InterfacesSoftware
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2BB2B2C
Highlights
1 PatentsVerified
Tags
digital-healthcaresaasdrug-discoverydrug-developmentpharmaceuticals
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | remepy.com/ |
|---|---|
| linkedin.com/company/82435157 |
Identifiers & details
| Founded | 2021-12 |
|---|---|
| Employees (exact) | 59 |
Radar intelligence
Patents
| EPO | 3 |
|---|
Publications (Crossref)
| Works | 2 |
|---|
GitHub
| Top repos | research-pages, flutter-plugins, better_player_plus, flutter_packages, betterplayer |
|---|
App Store
| App | Rating | Ratings |
|---|---|---|
| TGCT & Me |
Web history (Wayback)
| Domain | remepy.com |
|---|
Certificate / subdomain footprint
| Subdomains | 9 |
|---|